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Ischemia/reperfusion (I/R) of several organs results in complement activation, but the kidney is unique in 
that activation after I/R occurs only via the alternative pathway. We hypothesized that selective activation of 
this pathway after renal I/R could occur either because of a loss of complement inhibition or from increased 
local synthesis of complement factors. We examined the relationship between renal complement activation 
after I/R and the levels and localization of intrinsic membrane complement inhibitors. We found that loss 
of polarity of complement receptor 1–related protein y (Crry) in the tubular epithelium preceded activation 
of the alternative pathway along the basolateral aspect of the tubular cells. Heterozygous gene-targeted mice 
that expressed lower amounts of Crry were more sensitive to ischemic injury. Furthermore, inhibition of Crry 
expressed by proximal tubular epithelial cells in vitro resulted in alternative pathway–mediated injury to the 
cells. Thus, altered expression of a complement inhibitor within the tubular epithelium appears to be a criti-
cal factor permitting activation of the alternative pathway of complement after I/R. Increased C3 mRNA and 
decreased factor H mRNA were also detected in the outer medulla after I/R, suggesting that altered synthesis 
of these factors might further contribute to complement activation in this location.
*OUSPEVDUJPO
Complement activation has been shown to be an important event 
in the development of ischemic acute renal failure (ARF) in mice. 
Studies in complement-deficient mice have shown that these mice 
are protected from renal failure after ischemia/reperfusion (I/R) 
(1, 2), and that generation of the anaphylatoxin C5a (3) and the 
membrane attack complex (2) may contribute to the pathogenesis 
of ischemic ARF. Treatment with agents that inhibit the comple-
ment cascade at specific steps during the activation cascade has 
proven effective at ameliorating ischemic ARF (3, 4). Determining 
the initiating mechanisms of complement activation after renal 
I/R is essential to the effective use of complement inhibitors for 
the treatment and prevention of ischemic ARF.
Complement activation after renal I/R occurs via the alterna-
tive pathway (1) and is independent of natural antibody (5). In 
contrast, I/R injury of other organs such as the heart, intestine, 
and skeletal muscle appears to involve activation of the classical 
pathway of complement. Complement activation after intestinal 
I/R, for example, is the result of natural antibodies that bind to 
neoantigens exposed within the ischemic bowel (6, 7). Cardiac 
I/R also appears to involve classical pathway activation by anti-
bodies that recognize newly exposed antigens (8). Renal I/R there-
fore involves unique mechanisms of complement activation.
The alternative pathway is ordinarily activated at low levels via 
an enzymatic process, called “tickover,” which results in continu-
ous low-level production of C3b. When C3b binds covalently to an 
activating surface, such as a bacterial cell wall, it is stabilized such 
that it can combine with factor B to create the alternative pathway 
C3 convertase. Such activation of the alternative pathway does not 
usually cause injury to self cells due to the presence of membrane-
bound and fluid-phase complement regulatory proteins (9). These 
inhibitors are essential to prevent complement-mediated injury 
to the host, and deficiency of complement inhibitors can lead to 
spontaneous injury. For example, humans, pigs, and mice deficient 
in the fluid-phase factor H spontaneously develop membranopro-
liferative glomerulonephritis (10), the expression of dysfunctional 
CD46 is associated with development of the hemolytic uremic 
syndrome (11, 12), and paroxysmal nocturnal hemoglobinuria is 
associated with deficiencies of decay-accelerating factor (DAF, also 
known as CD55) and CD59 (13).
Local synthesis of complement components has also emerged 
as an important cause of complement activation and tissue injury 
in some models. For instance, in a murine renal transplant model, 
synthesis of C3 by the kidney was found to contribute to comple-
ment activation within the tubulointerstitium and, as opposed to 
serum C3, to be essential to graft loss (14).
Renal I/R in the mouse (1) and in humans (15) leads to the 
marked deposition of complement activation products along 
the tubular basement membrane. Although several inhibitors 
of complement activation are present within the mouse kidney, 
only complement receptor 1–related protein y (Crry) is present on 
mouse tubular epithelial cells (16), the cells primarily injured dur-
ing I/R. DAF and CD59 expression is limited to the glomeruli and 
Nonstandard abbreviations used: ARF, acute renal failure; ATN, acute tubular 
necrosis; Crry, complement receptor 1–related protein y; DAF, decay-accelerating fac-
tor; I/R, ischemia/reperfusion; LDH, lactate dehydrogenase; PTEC, proximal tubular 
epithelial cell; SUN, serum urea nitrogen.
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renal arteries (17, 18). Deficiency in DAF alone or DAF and CD59 
results in vascular complement activation after I/R and worse 
renal injury (19, 20). However, substantial vascular complement 
activation does not occur in wild-type mice after I/R (2). Therefore, 
in the normal host these particular inhibitors must retain their 
function, preventing further injury. In contrast, the activation of 
complement along the tubular basement membrane of wild-type 
mice after I/R suggests that local inhibition by Crry is either hin-
dered or overwhelmed.
Given the importance of membrane-
bound Crry for the prevention of alternative 
pathway complement activation and tubular 
injury, we hypothesized that altered expres-
sion or localization of Crry by tubular epi-
thelial cells might contribute to the activa-
tion of complement after I/R, or that local 
synthesis of complement C3 or factor B in 
response to I/R could overwhelm tubular-
intrinsic Crry. Therefore, we set out to study 
the effects of renal ischemia upon Crry and 
the relation of changes in Crry expression, 
local synthesis of complement components, 
and complement activation. We found 
that altered tubular expression of Crry pre-
cedes, and appears to permit, complement 
activation along the basolateral aspect of 
the tubules. Furthermore, C3 mRNA was increased and factor H 
mRNA was decreased in the outer medulla after I/R, indicating 
that altered synthesis of these factors might further contribute to 
alternative pathway activation at this location. Understanding the 
mechanisms whereby intrinsic complement inhibitors are unable 
to control activation may help in the rational use of complement 
inhibitors as therapeutics for the prevention of ischemic ARF. 
These studies may also further our understanding of more general 
inflammatory responses to injury.
3FTVMUT
Localization of intrinsic complement inhibitors within the kidney. Frozen 
sections of kidneys from unmanipulated mice were examined by 
immunofluorescence to determine the localization of the mem-
brane-bound complement inhibitors. Consistent with previous 
reports (14), Crry was heavily expressed within the glomeruli as 
well as the tubules (Figure 1). Crry in the proximal tubules was 
polarized to the basolateral surface of the epithelial cells. Expres-
sion was contained within the basement membrane, and no Crry 
was detectable within the cytoplasm or brush border. To further 
evaluate Crry expression by proximal tubular cells, immunogold 
labeling and evaluation by electron microscopy were performed 
on rat kidneys (Figure 2). Labeling within both the apical (34 ± 4 
particles/field, n = 22 fields) and basal regions (67 ± 8 particles/
field, n = 19 fields) was significantly above background label-
ing with nonimmune serum (12 ± 2 particles/field, n = 10 fields; 
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unpaired Student’s t test). Labeling in the region of the basolateral 
cell surface was significantly higher than that within the apical 
brush border (P < 0.001, unpaired Student’s t test). As previously 
reported (17, 18), DAF and CD59 were expressed within the glom-
eruli and vasculature, but not in the tubules (Figure 1).
Complement activation is an early event after renal I/R. Mice were 
subjected to 24 minutes of bilateral renal ischemia or sham sur-
gery and were sacrificed after 0, 2, 6, 24, and 48 hours of reperfu-
sion. Serum was collected for serum urea nitrogen (SUN) mea-
surements, and kidneys were evaluated for tubular injury and 
complement C3 deposition. Consistent with previous reports, 
sham-treated animals demonstrated small areas of C3 deposition 
(Figure 3A) along the tubular basement membrane of approxi-
mately 10–15% of the tubules in the cortex and outer stripe of 
the outer medulla (1, 21).
When tubules within the outer medulla were examine by fluores-
cent microscopy, a significant increase in the percentage of tubules 
showing complement deposition along the tubular basement 
membrane was seen by 6 hours of reperfusion (Figure 3A), simi-
lar to results previously reported by other groups (22). The degree 
of tubules showing complement deposition peaked at 24 hours of 
reperfusion, involving 46–75% of the tubules, and returned to base-
line by 48 hours of reperfusion. Western blot analysis of total kid-
ney lysates demonstrated a clear increase in complement activation 
products after ischemia and 24 hours of reperfusion (Figure 3D).
Although some epithelial cell swelling and brush border injury 
were evident within 6 hours of reperfusion (Figure 3B), the acute 
tubular necrosis (ATN) grade did not significantly increase until 
after 24 hours of reperfusion and returned to baseline by 48 
hours of reperfusion (Figure 3B). Thus, complement activation 
is an early event that precedes severe morphological injury after 
I/R. Although SUN levels did not significantly increase until after 
24 hours of reperfusion (Figure 3C), this was expected because 
serum markers do not reflect changes in renal function until a 
new steady state is reached.
Crry levels in the whole kidney do not significantly change after I/R. Crry 
is present in multiple isoforms in the kidney (23). Analysis of pro-
tein from immortalized proximal tubular epithelial cells (PTECs) 
by Western blot revealed that most of the Crry in proximal tubular 
cells was of the 53-kDa isoform (Figure 4A). Protein from rat kid-
neys demonstrated that 53-kDa Crry was present in basolateral 
membrane–enriched fractions but not in brush border–enriched 
fractions (Figure 4B). Blotting for type IIa Na/Pi cotransporter, 
which is known to be expressed on the apical brush border, was 
stronger on the brush border–enriched fraction. As further evi-
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other 2 Crry isoforms were not detected in the basolateral mem-
brane–enriched fraction. When protein was isolated from whole-
kidney sections, little difference in overall levels of Crry was dis-
cerned (Figure 4C), likely due to the fact that Crry is expressed in 
glomeruli and in tubules throughout the kidney. However, a trend 
toward decreased expression of the 53-kDa isoform was seen after 
6 hours of reperfusion. Semi-quantitative PCR was performed on 
tissue isolated from the outer medulla (Figure 4D). A trend toward 
increased mRNA for Crry was seen after 6 hours of reperfusion.
Altered Crry localization precedes complement activation. As discussed 
above, Crry is the only complement inhibitor expressed on the sur-
face of renal tubules. At baseline, Crry was polarized to the baso-
lateral aspect of the renal tubules (Figure 1), abutting the site of 
occasional focal C3 deposition along the tubular basement mem-
brane (Figure 5A). In kidneys subjected to 24 minutes of ischemia 
this polarity was lost before reperfusion, and Crry could be seen 
within the tubule lumen (Figure 5B). As shown in Figure 3, the 
tubules showed signs of injury at these early time points but did 
not yet show necrosis. The altered Crry expression is therefore a 
biochemical change of non-necrotic tubules. After 6 and 24 hours 
of reperfusion (Figure 5, C and D), individual tubules demonstrat-
ed little remaining Crry. Those tubules that no longer demonstrat-
ed Crry expression had C3 deposited along their circumference. By 
48 hours of reperfusion Crry still appeared in the cytosol but was 
also seen concentrated at the basolateral surface, and complement 
deposition had nearly returned to baseline (Figure 5E).
Because Crry appeared in the tubular lumen after ischemia, we 
examined the urine for the presence of Crry. It is known that PTECs 
shed F-actin–containing membrane vesicles into the tubular lumen 
after I/R (24). We found that the urinary sediment of mice subjected 
to I/R contained both F-actin and Crry (Figure 5F). This indicates 
that loss of Crry in the blebs and vesicles shed in the urine after I/R 
partially accounts for the absence of Crry in some tubular segments.
Lower-powered views of kidneys stained for Crry and C3 demon-
strated that Crry and C3 did not colocalize along the tubules. At 
baseline (Figure 6A), Crry was polarized to the basolateral aspect 
of tubules, and sporadic patches of C3 were seen along the tubular 
basement membrane. Little colocalization (yellow) was seen.
In order to quantitate colocalization of Crry and C3, we performed 
digital microscopy and measured the color intensity at each wave-
length (Figure 6, D and E). Pixels were plotted according to their 
Crry and C3 intensity, and the number of pixels within the image 
that had a given staining intensity was indicated by color. A histo-
gram of Crry and C3 intensity (Figure 6D) showed that there was 
virtually no colocalization of C3 and Crry. Pixels with a high inten-
sity of both markers would map to the upper right quadrant. Very 
few pixels were present within this quadrant, indicating that those 
pixels with a high intensity for Crry staining did not have abun-
dant C3. After 24 hours of reperfusion (Figure 6, C and E) there was 
much greater overall C3 deposition than at baseline, but there was 
still little, if any, colocalization of C3 and Crry. Renal I/R injury is 
patchy in nature, and some tubules retained their polarity (Figure 
6C, arrows) even in areas of extensive injury. Consistent with the 
histogram in Figure 6E, those tubules that retained the polarity of 
Crry showed little C3 deposition, whereas those with more severely 
altered Crry localization showed extensive C3 deposition.
Our results demonstrate that Crry localization was altered 
during renal ischemia prior to complement deposition and that 
tubules that retained Crry expression showed little C3 deposition. 
These data suggest that altered Crry localization is permissive of 
complement activation and that altered complement inhibition is 
a necessary event in the activation of complement after renal I/R. 
Although overall expression of Crry in the kidney did not signifi-
cantly decrease (Figure 4), altered expression of Crry specifically on 
the surface of the tubules appeared to permit complement activa-


























Downloaded on July 24, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/24521
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 116   Number 2   February 2006 
Altered Crry localization occurs primarily in the proximal tubule. Dual 
staining of kidney sections for Crry and a distal tubule marker 
revealed that altered Crry localization occurred primarily in proxi-
mal tubules (Figure 7A). It has long been known that Na/K-ATPase, 
another protein polarized to the basolateral aspect of PTECs, is 
associated with the actin cytoskeleton. Many studies have shown 
that I/R causes Na/K-ATPase to lose its polarity, and that after I/R 
the protein is seen diffusely throughout the cell cytoplasm (25, 
26). Dual staining for Crry and Na/K-ATPase demonstrated that 
these proteins colocalized to the basolateral membrane of proxi-
mal tubules at baseline (Figure 7B). After I/R both shifted into the 
cytoplasmic domain. Colocalization of the proteins was weaker 
after I/R, however, suggesting distinct subcellular localizations.
Crry shifts from a triton-insoluble to a triton-soluble form after I/R. The 
polarity of many transmembrane proteins is maintained by attach-
ment to the actin cytoskeleton (27), an association that can render a 
protein triton insoluble. A change in a renal tubular protein’s solu-
bility in triton after I/R may therefore reflect the disruption of this 
cytoskeletal attachment (25). To explore the possibility that tubular 
Crry is attached to the cytoskeleton, we examined the triton solubil-
ity of Crry before and after I/R. At baseline, approximately half of 
the 53-kDa Crry isoform was present in the triton-extractable frac-
tion of whole-kidney sections (Figure 7C). After I/R, however, nearly 
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other isoforms, in contrast, were primarily triton insoluble in both 
nonischemic and postischemic samples. This supports the hypoth-
esis that the polarization of 53-kDa Crry in tubular epithelial cells is 
dependent upon attachment to the cytoskeleton, and the disruption 
of this attachment explains the loss of polarity seen after I/R.
Deficiency of Crry renders mice susceptible to renal I/R injury. To con-
firm that the loss of inhibition by Crry is an important event in the 
pathogenesis of ischemic ARF and complement activation, we sub-
jected Crry-deficient and wild-type mice to a milder renal insult 
(Figure 8). Crry+/– mice do not directly address the issue of redistri-
bution per se. They do, however, address the issue of the “concen-
tration” of the complement inhibitor at the site of activation. We 
hypothesized that loss of functional Crry at the basolateral tubule 
would render the tubules more susceptible to injury, whether due 
to redistribution, targeted gene deletion, or the exogenous admin-
istration of an inhibitor of Crry (28). We therefore predicted that 
mice expressing less Crry at this location in the 
first place are more susceptible to complement 
activation. When subjected to 20 minutes of isch-
emia and 24 hours of reperfusion, Crry+/– mice 
had significantly greater SUNs (111 ± 18 versus 
52 ± 8 mg/dl; P < 0.01) and significantly greater 
morphological injury (average ATN score, 3.9 ± 0.3 
versus 2.56 ± 0.6; P < 0.05) than did wild-type con-
trols. Thus, mice that express decreased levels of 
Crry develop more severe injury in response to a 
mild ischemic insult.
Crry is critical for protecting PTECs in culture from 
alternative pathway–mediated injury. Complement 
activation may injure the tubular epithelium 
directly or through indirect effects such as altera-
tions to the vasculature or chemotaxis of inflam-
matory cells. In order to confirm that PTECs 
themselves are the direct target of local alternative 
pathway–mediated injury when Crry function is impaired, we devel-
oped an in vitro model of PTEC injury. We incubated PTECs with 
fresh mouse serum in a buffer solution containing 10 mM EGTA 
in order to inhibit classical pathway activation. Treatment of these 
cells with an inhibitory rat IgG1 mAb to Crry in order to suppress 
the function of this protein caused injury to the cells as assessed by 
lactate dehydrogenase (LDH) release (Figure 9), whereas the addi-
tion of control rat IgG1 had no effect. Similar injury was also seen 
when Fab fragments of the inhibitory antibody were used, indicat-
ing that the injury is not a nonspecific effect of antibody binding 
or Fc-mediated complement activation. We then added the same 
inhibitor to a reaction mix in which the alternative complement 
pathway was selectively blocked with a mAb to factor B. Without 
an intact alternative pathway, blocking the function of Crry did not 
result in injury to the cells. Thus, functional Crry on the surface of 
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ed cellular injury. As described above, Crry was the only membrane-
bound inhibitor of complement expressed by PTECs. The loss of 
complement inhibition by Crry on the surface of PTECs, whether 
by the application of an inhibitor of this protein in vitro or by the 
altered expression of Crry after ischemia, is therefore sufficient to 
permit alternative pathway–mediated injury of the cells.
Local synthesis of alternative pathway components after I/R. In other 
models, local synthesis of complement by the kidney has been 
found to be an important cause of complement activation and 
tissue injury (14). The kidney has been shown capable of synthe-
sizing C3, factor B, and factor H (29, 30), and renal I/R in rats 
was demonstrated to increase renal C3 expression (31). To deter-
mine whether the complement activation that occurs after I/R 
is enhanced by local synthesis of alternative pathway substrates, 
mice were subjected to sham surgery or to I/R. After variable 
times of reperfusion, the outer medulla (where C3 deposition is 
heaviest) was dissected out, and real-time PCR was performed to 
quantitate expression of C3, factor B, and factor H (Figure 10). C3 
mRNA did not significantly increase at any of the times of reper-
fusion, although at 24 hours there was a trend toward increased 
C3 mRNA. Because of the tendency toward increased C3 synthesis 
after I/R, we more specifically evaluated the tubules of the outer 
medulla for changes in C3 synthesis using in situ hybridization 
(Figure 10). Local synthesis of C3 was evident in the outer medul-
las of sham-treated animals, and synthesis in this region increased 
after 24 hours of reperfusion. Factor H mRNA in the outer medul-
la was significantly decreased from baseline after 2 and 24 hours of 
reperfusion, as determined by real-time PCR. Thus increased local 
synthesis of C3 and decreased synthesis of factor H may further 
facilitate alternative pathway activation during reperfusion. Given 
the basal synthesis of C3 in this region of the kidney, it is also pos-
sible that a pool of locally produced C3 contributes to the activa-
tion that occurs after I/R. Furthermore, even small increases in 
C3 synthesis may serve to initiate a much larger degree of comple-
ment activation, subsequently utilizing circulating components of 
the alternative pathway.
%JTDVTTJPO
Complement activation by the alternative complement pathway is 
an important pathogenic event after I/R (1, 2). C3 deposition pri-
marily occurs along the tubular basement membrane of proximal 
tubules in the outer stripe of the outer medulla, and Crry is the 
only membrane-bound inhibitor of complement expressed by the 
tubular epithelial cells in this segment of the nephron. At baseline, 
Crry is polarized to the basolateral aspect of the tubules, adjacent 
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deficient in DAF and CD59 are susceptible to complement-medi-
ated injury after renal I/R (19, 20), likely due to complement acti-
vation along the vascular endothelium (19). However, extensive 
complement activation after I/R in wild-type mice occurs along 
the tubular epithelium. Thus, I/R must cause the Crry expressed 
by these cells to become overwhelmed.
We have demonstrated herein that ischemia quickly led to altered 
localization of Crry. Even before reperfusion of the kidney began, 
Crry shifted away from the basolateral membrane and into the cyto-
plasm. Although levels of Crry in the whole kidney remained close 
to baseline after I/R, immunofluorescence demonstrated that levels 
of the protein in proximal tubules in the outer stripe of the outer 
medulla were much lower within 6 hours of reperfusion, and Crry-
containing blebs appeared in the urine after I/R. A trend toward 
increased Crry mRNA in the outer medulla suggests that replace-
ment of the lost Crry by the repaired kidney is accomplished by syn-
thesis of new protein. Complement deposition along the tubules 
occurred only after the loss of Crry at this location. Despite abun-
dant C3 deposition after I/R there was little colocalization of C3 
and Crry, suggesting that the loss of Crry at the basolateral surface 
is necessary for activation of the alternative pathway. Conversely, 
those tubules that retained polarized expression of Crry along their 
surface demonstrated little C3 deposition.
Crry is analogous to other polarized membrane-associated pro-
teins such as Na/K-ATPase, which has long been known to lose its 
polarity during ischemia (25). Like Na/K-ATPase, Crry within the 
kidney also shifted from a triton-insoluble fraction to an almost 
entirely triton-soluble state during ischemia. As is the case with 
Na/K-ATPase, this biochemical shift of Crry probably reflects the 
loss of a stabilizing association, such 
as with the actin cytoskeleton. The 
rapid change in the triton solubil-
ity of Crry and movement of it away 
from the basolateral membrane pre-
ceded detectable activation of com-
plement on the tubular cells.
Treatment with an inhibitor of 
Crry leads to increased complement 
activation and spontaneous tubu-
lar injury in rats (28). Furthermore, 
we have found that mice expressing 
lower levels of Crry (Crry+/– mice) 
were more susceptible to renal I/R. 
This supports the hypothesis that a 
decreased concentration of Crry at 
the basolateral aspect of the PTEC 
(whether due to a targeted gene 
mutation, the administration of 
an exogenous inhibitor, or altered 
expression in response to I/R) leaves 
the tubules more susceptible to com-
plement-mediated injury. When the 
function of Crry expressed by PTECs 
in culture was blocked, the cells were 
injured in the presence of alternative 
pathway–sufficient serum. Blocking 
the function of Crry did not injure 
PTECs when the alternative comple-
ment pathway in the serum to which 
they were exposed was also inhibited. 
This confirms the importance of Crry for the prevention of autolo-
gous complement-mediated tubular injury. Loss of this protection, 
due to either congenital deficiency, exogenous inhibition, or loss 
of polarity after I/R, permits uncontrolled activation of the alter-
native pathway on the surface of tubular epithelial cells. A study 
in which exogenous Crry-Ig was administered to mice before they 
underwent I/R did not find that this agent significantly protected 
the mice from ARF (32). All of the mice in this study were also 
treated with heparin, however, and heparin is a very effective com-
plement inhibitor (33). It is therefore likely that heparin inhibited 
complement activation in both experimental groups, obscuring 
any potential benefit derived from Crry-Ig.
Previous studies have shown that PTECs in culture activate the 
alternative pathway when they are heat killed (34), and that such 
activation results in an inflammatory response by the cells (35). 
It is possible that altered expression of Crry is a general response 
to injury of these cells, and that complement activation by tubu-
lar epithelial cells also occurs in other forms of tubular injury. In 
support of this, we have observed that glycerol-induced rhabdo-
myolysis (a model of toxin-induced ATN) is also characterized 
by decreased tubular Crry and peritubular C3 deposition (our 
unpublished observations).
We have examined the effects of I/R on the intrinsic inhibitors 
of complement activity and on local synthesis of the complement 
components. Several previous studies have highlighted the con-
tribution of locally synthesized C3 to the development of renal 
injury (14, 31). Real-time PCR of samples made from the outer 
medulla demonstrated that there was basal synthesis of C3 in this 
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by in situ hybridization. In contrast, local synthesis of factor H 
was decreased after I/R. Thus, I/R causes a shift toward greater C3 
production and decreased factor H synthesis in the outer medulla 
during the period when Crry expression is most disrupted.
It is possible that I/R of the kidney results in the generation of 
specific alternative pathway activators. Moieties such as endo-
toxin, IgA, ammonia, and nephritic factor can cause activation of 
the alternative pathway. We have conducted experiments in which 
mice were fed water containing potassium bicarbonate or ammo-
nium chloride in an effort to alter the renal ammonia content 
and therefore alter the magnitude of complement activation after 
I/R. These manipulations did not detectably affect the degree of 
complement activation in the kidney either before or after I/R (our 
unpublished observations). Although the presence of ammonia 
may be an important component of peritubular alternative path-
way activation, changes in local ammonia content do not explain 
the increase in complement activation seen after I/R. There are no 
obvious mechanisms for accumulation of the other known alter-
native pathway activators in this model, but we have not excluded 
the possibility that ischemic tubular epithelial cells generate and 
release proteases that could contribute to this process.
The polarization of proteins within renal epithelia is essential to 
the proper function of the kidney. Molitoris et al. (36) demonstrated 
that the basolateral polarization of Na/K-ATPase is lost after I/R. 
Disruption of the polarized organization of proteins within the 
plasma cell membrane results in the loss of vectorial transport 
across the epithelium, loss of tight junctions between epithelial 
cells, and loss of integrin-mediated adhesion of epithelial cells to 
the extracellular matrix (37). Our results demonstrate that the loss 
of polarized expression of Crry renders the epithelial cells prone to 
complement activation and further injury. Furthermore, the genera-
tion of proinflammatory complement activation products such as 
the anaphylatoxin C5a or the generation of other proinflammatory 
cytokines caused by uncontrolled complement activation along the 
tubular epithelium (35) may have widespread and deleterious conse-
quences for the host. Insults to the precise organization of the tubu-
lar epithelium therefore impair renal function as well as contribute 
to the local, and possibly systemic, inflammatory response.
We previously found that human ATN is also characterized by 
alternative pathway activation along the proximal tubule (15). 
Membrane cofactor protein (MCP, also 
known as CD46 ), a human functional ana-
log of Crry, is expressed by human PTECs 
in a polarized fashion (38). Studies have 
demonstrated that the polarity of PTECs 
is disrupted in human ATN (39). Loss of 
polarity of MCP after I/R may also there-
fore occur, permitting activation of the 
alternative pathway.
Our results may also have broader impli-
cations regarding the regulation of comple-
ment activation. The importance of the 
complement system in the pathogenesis 
of immune complex diseases as well as the 
mechanisms of complement activation 
in these diseases are well established. The 
complement system has recently been impli-
cated in a large number of Ig-independent 
diseases (40–42), however, and the cause of 
activation in these diseases has yet to be fully 
elucidated. Although genetic complement deficiencies are known 
to cause autoimmune disease (10, 13), nongenetically determined 
loss of complement inhibition of a specific organ or cell type may 
significantly contribute to inflammation and organ injury. Stud-
ies in rats have shown that CD59 expression in the myocardium 
decreases after ischemia, perhaps allowing greater assembly of the 
membrane attack complex (43), although in that setting comple-
ment activation precedes loss of inhibition. Anoxic injury of human 
endothelial cells in culture also results in diminished expression of 
cell surface complement inhibitors and activation of the comple-
ment system on the cell surface (44). Given the need for constant 
inhibition of the alternative pathway to prevent spontaneous inju-
ry, it is possible that other injuries in various tissues may impede 
this tonic inhibition and result in alternative pathway activation. 
Locations such as the renal tubules that rely on only 1 complement 
inhibitor may be particularly vulnerable to such injuries.
We have demonstrated that altered localization and expression of 
renal tubular epithelial Crry is an early consequence of renal isch-
emia. The loss of inhibition by Crry is permissive of complement 
activation on the surface of epithelial cells and of the resultant com-
plement-mediated injury. These results explain the unique nature 
of complement activation in the kidney after I/R. Furthermore, 
these findings demonstrate that complement activation may be a 
response to any injury that alters host expression of complement 
inhibitors. Inhibition of the alternative pathway may be an effec-
tive means of ameliorating ischemic ARF. The loss of complement 
inhibition and the activation of the alternative pathway are early 
events after I/R, however, and exogenous inhibition may need to be 
performed soon after the ischemic event. The exact localization of 
cell surface complement inhibitors is clearly very important, and 
exogenous inhibitors of complement may not effectively prevent 
activation of complement on the epithelial cell surface if they do 
not achieve adequate levels specifically at this site.
.FUIPET
Experimental animals. C57BL/6J mice (The Jackson Laboratory) were used 
as wild-type mice for experiments examining the relationship of Crry 
expression and complement activation. Crry-deficient mice were gener-
ated as previously described (45). Mice that were heterozygous for Crry 
(Crry+/–), littermate controls, and C57BL/6J mice were used to test the 
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effects of Crry deficiency since homozygous deficiency is lethal in utero 
(45). Only male mice were used in this study because they demonstrate a 
higher level of complement activity and are more vulnerable to comple-
ment-mediated renal injury (32). Sprague-Dawley rats were used for isola-
tion of renal basolateral and brush border membranes and for immuno-
gold labeling. The animals were housed and maintained in the University 
of Colorado Center for Laboratory Animal Care in accordance with the 
NIH Guidelines for the Care and Use of Laboratory Animals. The study 
protocol was approved by the University of Colorado Health Sciences Cen-
ter Animal Care and Use Committee.
Antibodies and primers. The following antibodies were used for 
immunofluorescence: FITC-conjugated goat anti-mouse C3 (Cappel; MP 
Biomedicals) diluted 1:50 with PBS, rat anti-mouse Crry (BD Biosciences — 
Pharmingen) diluted 1:150, rabbit anti-human C3d (Dako) diluted 1:150, 
mouse anti- Na/K-ATPase α-1 (Upstate USA Inc.) at a concentration of 
0.5 μg/ml, rabbit anti-mouse collagen type IV (Chemicon International) 
diluted 1:400. FITC-conjugated Arachis hypogaea (Sigma-Aldrich) was used 
as a distal tubule marker (46). A polyclonal rabbit anti-DAF antibody and 
a mouse anti-CD59 mAb (a generous gift of S. Tomlinson, Medical Uni-
versity of South Carolina, Charleston, South Carolina, USA) were diluted 
1:300. To stain F-actin, Alexa Fluor 350 phalloidin (Invitrogen Corp.) was 
diluted 1:40. For secondary antibodies, FITC-conjugated anti-rat IgG, 
rhodamine-conjugated anti-rabbit IgG, and FITC-conjugated anti-mouse 
IgG (Cappel; MP Biomedicals) were used at dilutions of 1:100, and Alexa 
Fluor 488–conjugated goat anti-rabbit IgG was used at a dilution of 1:400 
(Invitrogen Corp.). Two mAbs were used as complement protein inhibitors. 
The mAb 5D5 (47) was used to inhibit the function of cell-surface Crry, 
and mAb 1379 (48) was used to block mouse alternative pathway activity. 
Fab fragments of 5D5 were also made using papain-agarose (MP Biomedi-
cals) according to the manufacturer’s instructions.
For Western blot analysis, a peroxidase-conjugated goat anti-mouse C3 
(Cappel; MP Biomedicals) was used at a dilution of 0.3 μg/ml. A polyclonal 
antibody to Crry (23) and a polyclonal anti–type IIa Na/Pi cotransporter 
antibody (49) were used at dilutions of 1 μg/ml, followed by incubation 
with peroxidase-conjugated goat anti-rabbit IgG (Sigma-Aldrich).
Induction of ischemic ARF. Mice weighing 20–25 g were anesthetized with 
300 μl 2,2,2-Tribromoethanol (Sigma-Aldrich) injected intraperitoneally. 
After the mice were anesthetized they were placed on a heating pad to 
maintain their body temperature during surgery. Laparotomies were then 
performed, and the renal pedicles were located and isolated by blunt dissec-
tion. The pedicles were clamped with surgical clips (Miltex Inc.), and occlu-
sion of blood flow was confirmed by visual inspection of the kidneys. The 
clamps were left in place for 24 minutes and then released. This time of 
ischemia was chosen to obtain a reversible model of ischemic ARF with a 
minimum of vascular thrombosis and to avoid animal mortality. For experi-
ments comparing Crry+/– mice with Crry+/+ controls, an ischemic time of 20 
minutes was used. The shorter ischemic time was chosen because it causes 
milder injury, allowing for detection of mouse strains with greater suscepti-
bility to I/R injury. The kidneys were observed for approximately 1 minute 
to ensure blood reflow, then fascia and skin were sutured with 4-0 silk (U.S. 
Surgical). Sham surgery was performed in an identical fashion, except that 
the renal pedicles were not clamped. The mice were volume resuscitated 
with 0.5 ml of normal saline and kept in an incubator at 29°C to maintain 
body temperature. After 0, 2, 6, 24, or 48 hours of reperfusion the mice were 
anesthetized, and blood was obtained by cardiac puncture. Laparotomy was 
performed and the kidneys were harvested.
SUN measurements. SUN was determined for each mouse using a Beck-
man Autoanalyzer (Beckman Coulter).
Renal morphology. After the kidneys were removed from the mice, sagit-
tal sections were fixed in 4% paraformaldehyde. After being embedded in 
paraffin, 4-μm sections were cut and stained with periodic acid–Schiff. The 
sections were evaluated by a renal pathologist (D. Ljubanovi´c) in a blinded 
fashion. The cortex and outer stripe of the outer medulla were assessed 
for epithelial necrosis, loss of brush border, tubular dilatation, and cast 
formation. At least 10 fields (magnification, ×400) were reviewed for each 
slide, and the percentage of tubules displaying these findings was deter-
mined. Kidney sections were scored as follows based on the percentage of 
affected tubules: 0, none; 1, less than 10%, 2, 10–25%, 3, 26–45%, 4, 46–75%, 
5, greater than 75%.
Immunofluorescence and in situ hybridization. For immunofluorescence, 
sagittal sections of the kidneys were snap frozen in OCT compound 
(Sakura Finetek). Sections (4 μm) were cut with a cryostat and stored at 
–70°C. The slides were later fixed with acetone and incubated with the 
primary antibodies. After hybridization with antibodies was complete the 
slides were counterstained with hematoxylin (Vector Laboratories). Tissue 
sections were incubated with secondary antibodies alone to ensure the 
specificity of antibody binding.
To detect the presence of Crry in the urine, immunofluorescence was 
performed on urine sediments as previously described (24). Upon sacrifice 
after 6 hours of renal reperfusion, urine was expressed from the bladder 
and collected at the tip of the urethra. Urine was centrifuged at 4°C for 10 
minutes at 15,996 g. The pellets were then fixed for 1 hour at room tem-
perature in 3% paraformaldehyde in PBS (pH 7.4). The sediment was then 
washed 3 times in PBS for 5 minutes and recentrifuged for 5 minutes at 
15,996 g. The pellets were incubated for 10 minutes in 0.1% Triton X-100 
(Sigma-Aldrich) in PBS. Nonspecific binding was blocked with 2% BSA in 
PBS for 1 hour. The pellets were then incubated with rat anti-mouse Crry 
and Alexa Fluor 350 phalloidin. To ensure that antibody binding was spe-
cific, anti–secondary antibody alone was used as a control.
Imaging was performed on a Nikon T2000 inverted fluorescent micro-
scope and slidebook software (version 3.0; Intelligent Imaging Innovations 
Inc.). Intensity histograms were obtained using a Zeiss LSM 510 Meta con-
focal microscope running Zeiss software version 3.2 Service Pack 2.
To examine kidneys for the local production of C3, 16-μm kidney sec-
tions were fixed for 15 minutes in cold 4% paraformaldehyde. The sections 
were then hybridized with a digoxin-labeled antisense probe to mouse C3 
(Table 1) according to the manufacturer’s instructions (GeneDetect.com). 
The bound probe was detected using alkaline phosphatase–labeled anti-
digoxigenin Fab fragments and NBT/BCIP tablets (Roche Diagnostics 
Corp.). Digoxin-labeled sense probe to mouse C3 was used to confirm the 
specificity of the binding.
Immunogold labeling of Crry. Rat kidneys were fixed by perfusion with 2% 
formaldehyde and 0.1% glutaraldehyde in 0.1 M sodium cacodylate, pH 
7.35, as previously described (50). The samples were dehydrated and embed-
ded in LR Gold resin (Polysciences Inc.). Ultrathin sections were then pre-
pared using nickel grids and stained for Crry. The grids were floated on 
droplets of PBS (10 minutes), 10% whole goat serum (10 minutes), and 
either droplets of rabbit anti-Crry at a dilution of 20 μg/ml or nonimmune 
rabbit serum diluted 1:150 (45 minutes). The grids were washed using 
droplets of PBS for a total of 20 minutes, after which each was floated 
on 10 μl of goat anti-rabbit IgG Fab2 conjugated to 10-nm gold particles 
(Ted Pella Inc.). After washing the grids with PBS, they were stained for 
6 minutes with 2% uranyl acetate, washed with water, and air dried. The 
sections were then viewed using a Tecnai G2 microscope (FEI Co.). After 
identifying PTECs, images were taken at a magnification of ×18,500 in the 
apical and basal regions of the cells, and the number of gold particles seen 
in each view were counted.
Western blot analysis. Renal tissue was homogenized in RIPA lysis buffer 
containing 1% Triton X-100, 0.5% deoxycholic acid, 150 mM NaCl, 20 mM 
β-glycerophosphate, 20 mM Tris-HCl (pH 8.0), 5 mM EGTA, 3 mM MgCl2, 
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0.1% SDS, 1 mM DTT, 50 μM Na3VO4, and 1 tablet of complete, EDTA-free 
protease inhibitor cocktail (Roche Diagnostics Corp.). Homogenates were 
centrifuged at 15,996 g for 15 minutes at 4°C, and the supernatant was col-
lected. Brush border and basolateral membranes from rat renal cortical tis-
sue were isolated as previously described (51). Briefly, kidneys were placed 
in cold isolation buffer containing 300 mM mannitol, 5 mM EGTA, 0.1 
mM PMSF, and 18 mM Tris (pH 7.4). Thin cortical sections were obtained 
and homogenized. Brush border and basolateral membranes were then iso-
lated by differential centrifugation, magnesium precipitation, and use of a 
discontinuous sucrose gradient (52). To isolate triton-soluble and -insolu-
ble protein fractions, kidneys were homogenized in a solution containing 
0.1% Triton X-100, 20 mM HEPES, 120 mM KCl, 12 mM NaCl, 1.62 mM 
MgSO4, 1 mM EDTA, 0.35 mM CaCl2, and 1 tablet of complete, EDTA-
free protease inhibitor cocktail (Roche Diagnostics Corp.). Samples were 
centrifuged at 35,000 g for 14 minutes at 4°C to separate the soluble and 
insoluble fractions. Because approximately two-thirds of cellular proteins 
are triton soluble (53), the insoluble pellet was resuspended at half the vol-
ume of buffer used for the initial homogenization. Protein concentrations 
for all of the samples were determined using the Bio-Rad protein assay 
(Bio-Rad Laboratories). Protein (50 μg) for each sample was resolved by 
electrophoresis with a 10% Bis-Tris polyacrylamide gel (Invitrogen Corp.) 
and transferred to a nitrocellulose membrane. The membrane was probed 
with antibody to Crry and visualized using a chemiluminescence detection 
kit (Amersham Biosciences).
Reverse transcription polymerase chain reaction. Kidneys were obtained from 
unmanipulated mice and mice subjected to ischemia and variable times 
of reperfusion. The outer medullary region of the kidney was manually 
dissected away from the inner medulla and the outer cortex, and RNA 
was isolated using TRIzol reagent (Gibco; Invitrogen Corp.). cDNA was 
generated from 3 μg RNA using MuLV Reverse Transcriptase (Applied 
Biosystems). Quantitative real-time PCR for C3, factor B, and factor H 
was then performed using the designated primers (Table 1). Appropri-
ate primers were designed using Beacon Designer software (version 
4.0; PREMIER Biosoft International). Samples were prepared using iQ 
Sybergreen Supermix (Bio-Rad Laboratories) and the iCycler iQ detec-
tion system (Bio-Rad Laboratories). Triplicate reactions for each sample 
were performed using the target primers and using cyclophilin primers 
to provide an internal control. Conventional PCR for Crry was performed 
in a GeneAmp 9700 PCR system (Applied Biosystems) after using cDNA 
from an unmanipulated kidney to determine the linear range of ampli-
fication. Control PCR was performed using primers for glyceraldehyde-
3-phosphate dehydrogenase. PCR products were run on 2% agarose gels 
and visualized with ethidium bromide.
In vitro assay of complement inhibition by Crry on PTECs. Boston University 
mouse proximal tubular cells (BUMPT cells) were generously provided 
to us by J. Schwartz (Boston University Medical Center, Boston, Massa-
chusetts, USA). This is a mouse PTEC line that was established from the 
immortoMouse (54). Cells were grown to confluence in DMEM supple-
mented with 10% fetal bovine serum, penicillin/streptomycin, and 0.2 
U/ml IFN-γ (PeproTech Inc.). After the cells reached confluence they were 
changed to 1:1 DMEM/Hams F12 supplemented with 5 mg/l transferrin 
(Invitrogen Corp.), 50 nM hydrocortisone (Sigma-Aldrich), and 5 mg/l 
insulin for 2 days. As a source of complement components, 10% serum 
from C57BL/6J mice was added to a reaction mix containing 5 mM MgCl2 
and 10 mM EGTA in PBS. Some of the cells were also treated with 100 
μg/ml 5D5, an inhibitory mAb to Crry (47), or the same concentration of 
control rat IgG1 (Sigma-Aldrich). To confirm that the effects of 5D5 were 
due to its inhibitory activity and a nonspecific effect of antibody bind-
ing, 70 μg 5D5 Fab were added to cells with serum and compared with 
cells treated with 5D5 IgG. Another group of cells was treated with 5D5 
after preincubating the mouse serum with 40 μg 1379, an inhibitory mAb 
to mouse factor B (an essential component of the alternative pathway). 
Cells were incubated for 10 minutes, and supernatant was then tested for 
LDH content. LDH was measured by the Cytotox-ONE assay (Promega) 
according to the manufacturer’s instructions, and the results were read 
on a Wallac 1420 fluorescence plate reader (PerkinElmer and Analytical 
Sciences Inc.) with an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm.
Statistics. Multiple-group comparisons were performed using ANOVA 
with post-test according to Newman-Keuls. Comparison between the 
control and Crry+/– groups was performed with the Mann-Whitney test. A 
P value of less than 0.05 was considered statistically significant. Results are 
reported as mean ± SEM.
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